Literature DB >> 75392

Flufenamic acid in treatment of primary spasmodic dysmenorrhoea. A double-blind crossover study.

L Kapadia, M G Elder.   

Abstract

A double-blind cross-over trial of flufenamic acid three times a day (200 mg) was carried out in forty-four patients with primary dysmenorrhoea. While on flufenamic for 3 months 82% of patients experienced significant pain relief. Associated gastrointestinal symptoms, i.e--vomiting and diarrhoea--were relieved in 66% and 52% patients respectively while on flufenamic acid. It is concluded that the fenamates are useful and safe drugs in the treatment of primary dysmenorrhoea.

Entities:  

Keywords:  Analgesia--therapeutic use; Diseases; Double-blind Studies; Dysmenorrhea; Menstruation Disorders; Research Methodology; Studies; Treatment

Mesh:

Substances:

Year:  1978        PMID: 75392     DOI: 10.1016/s0140-6736(78)91078-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Reading for Pleasure: Celtic and non-Celtic nostalgia.

Authors:  D Davies
Journal:  Br Med J       Date:  1979-08-18

2.  Effect of acetylsalicylic acid, paracetamol, and placebo on pain and blood loss in dysmenorrhoeic women.

Authors:  T Janbu; P Løkken; B I Nesheim
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

3.  Trial of the calcium antagonist nifedipine in the treatment of primary dysmenorrhoea.

Authors:  B Sandahl; U Ulmsten; K E Andersson
Journal:  Arch Gynecol       Date:  1979-08

Review 4.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

Review 5.  Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations.

Authors:  M Y Dawood
Journal:  Drugs       Date:  1981-07       Impact factor: 9.546

6.  Fenamates may antagonize the actions of prostaglandin endoperoxides in human myometrium.

Authors:  G J Sanger; A Bennett
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

7.  Flurbiprofen in the treatment of primary dysmenorrhoea.

Authors:  U R Krishna; S Naik; A Mandlekar; K C Gupta; V N Kulkarni; U K Sheth
Journal:  Br J Clin Pharmacol       Date:  1980-06       Impact factor: 4.335

Review 8.  Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors.

Authors:  A E Farah; F Rosenberg
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

9.  Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.

Authors:  Allan D Heibein; Baoqing Guo; Jason A Sprowl; David A Maclean; Amadeo M Parissenti
Journal:  BMC Cancer       Date:  2012-08-31       Impact factor: 4.430

10.  Impacts of diphenylamine NSAID halogenation on bioactivation risks.

Authors:  Mary Alexandra Schleiff; Sasin Payakachat; Benjamin Mark Schleiff; S Joshua Swamidass; Gunnar Boysen; Grover Paul Miller
Journal:  Toxicology       Date:  2021-06-06       Impact factor: 4.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.